Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Employees - 20,
CEO - Dr. Marc H. Hedrick M.B.A., M.D.,
Sector - Healthcare,
Country - US,
Market Cap - 13.17M
Altman ZScore(max is 10): -111.17, Piotroski Score(max is 10): 1, Working Capital: $-10292000, Total Assets: $6633000, Retained Earnings: $-493479000, EBIT: -12703000, Total Liabilities: $15582000, Revenue: $4269000
AryaFin Target Price - $-0.43 - Current Price $0.77 - Analyst Target Price $6.17
| Ticker | PSTV |
| Index | - |
| Curent Price | 0.77 |
| Change | -12.95% |
| Market Cap | 13.17M |
| Average Volume | 16.05M |
| Income | -12.98M |
| Sales | 5.82M |
| Book Value/Share | -1.52 |
| Cash/Share | 0.21 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 21 |
| Moving Avg 20days | -27.85% |
| Moving Avg 50days | -28.50% |
| Moving Avg 200days | -42.18% |
| Shares Outstanding | 11.79M |
| Earnings Date | Mar 27 AMC |
| Inst. Ownership | 16.02% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 2.26 |
| Price/Book | - |
| Price/Cash | 3.65 |
| Price/FCF | - |
| Quick Ratio | 0.31 |
| Current Ratio | 0.31 |
| Debt/Equity | - |
| Return on Assets | -144.03% |
| Return on Equity | - |
| Return on Investment | - |
| Gross Margin | 85.37% |
| Ops Margin | -252.32% |
| Profit Margin | -222.84% |
| RSI | 43.96 |
| BETA(β) | 0.85 |
| From 52week Low | 222.88% |
| From 52week High | -70.98% |
| EPS | -2.06 |
| EPS next Year | -0.69 |
| EPS next Qtr | -0.25 |
| EPS this Year | 60.68% |
| EPS next 5 Year | 49.80% |
| EPS past 5 Year | 46.51% |
| Sales past 5 Year | 383.24% |
| EPS Y/Y | 50.37% |
| Sales Y/Y | 18.54% |
| EPS Q/Q | 21.43% |
| Sales Q/Q | 7.54% |
| Sales Surprise | -6.40% |
| EPS Surprise | 23.50% |
| ATR(14) | 0.31 |
| Perf Week | -49.02% |
| Perf Month | 121.40% |
| Perf Quarter | -32.62% |
| Perf Year | -58.56% |
| Perf YTD | -32.62% |
| Target Price | 6.17 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer